BioNTech SE (22UA) - Total Liabilities
Based on the latest financial reports, BioNTech SE (22UA) has total liabilities worth €2.86 Billion EUR (≈ $3.35 Billion USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore BioNTech SE (22UA) cash conversion ratio to assess how effectively this company generates cash.
BioNTech SE - Total Liabilities Trend (2016–2024)
This chart illustrates how BioNTech SE's total liabilities have evolved over time, based on quarterly financial data. Check BioNTech SE liquidity resilience to evaluate the company's liquid asset resilience ratio.
BioNTech SE Competitors by Total Liabilities
The table below lists competitors of BioNTech SE ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
ABN Amro Group NV
AS:ABN
|
Netherlands | €386.17 Billion |
|
CMS Energy Corporation
NYSE:CMS
|
USA | $30.68 Billion |
|
Circle Internet Group, Inc.
NYSE:CRCL
|
USA | $73.76 Billion |
|
Reddit, Inc.
NYSE:RDDT
|
USA | $310.13 Million |
|
PulteGroup Inc
NYSE:PHM
|
USA | $5.02 Billion |
|
Epiroc AB (publ)
ST:EPI-A
|
Sweden | Skr38.10 Billion |
|
SAIC Motor Corp Ltd
SHG:600104
|
China | CN¥598.90 Billion |
|
Flex Ltd
NASDAQ:FLEX
|
USA | $15.70 Billion |
Liability Composition Analysis (2016–2024)
This chart breaks down BioNTech SE's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see BioNTech SE market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 7.12 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.15 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.13 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how BioNTech SE's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for BioNTech SE (2016–2024)
The table below shows the annual total liabilities of BioNTech SE from 2016 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | €3.12 Billion ≈ $3.65 Billion |
+12.98% |
| 2023-12-31 | €2.76 Billion ≈ $3.23 Billion |
-14.37% |
| 2022-12-31 | €3.22 Billion ≈ $3.77 Billion |
-18.13% |
| 2021-12-31 | €3.94 Billion ≈ $4.60 Billion |
+315.84% |
| 2020-12-31 | €946.77 Million ≈ $1.11 Billion |
+211.28% |
| 2019-12-31 | €304.15 Million ≈ $355.59 Million |
-21.20% |
| 2018-12-31 | €385.99 Million ≈ $451.26 Million |
-8.73% |
| 2017-12-31 | €422.92 Million ≈ $494.44 Million |
+18.10% |
| 2016-12-31 | €358.10 Million ≈ $418.66 Million |
-- |
About BioNTech SE
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies to treat cancer and infectious diseases in Germany. The company develops BNT111, which is in Phase 2 clinical trial for advance melanoma; BNT113, which is in Phase 2 clinical trial to treat head and neck squamous cell carcinoma; BNT116, which is in Phase I clinical trial for non-small cell lung cancer; BNT142, which… Read more